Zai Lab (ZLAB) Insider William Lis Sells $127K of Stock

William Lis, a key insider at Zai Lab Limited, sold 7,040 shares of the company on June 22, 2026. The shares were sold at an average price of $18.09 each, amounting to a total transaction value of $127,353.60. This planned sale was executed under a Rule 10b5-1 trading plan.

Insider Buying and Selling at Zai Lab Limited

William Lis was not the only insider active in June. On June 17, several insiders, including Nisa Leung, Leon Jr. Moulder, Richard Gaynor, John Diekman, and Lis himself, each acquired 22,371 shares. These transactions were not part of any pre-planned trading agreements.

Other Institutional Activity in Zai Lab Limited

RTW Investments, LP reduced its holdings in Zai Lab by 385,000 shares, bringing its total to approximately 6.57 million shares valued at $123.66 million. Meanwhile, RA Capital Management, L.P. opened a new position, now holding about 5.71 million shares worth $107.35 million. BAMCO Inc /NY/ increased its stake by 240,313 shares, ending with 1.66 million shares valued at around $31.19 million. Similarly, ADAR1 Capital Management, LLC added 178,847 shares, holding a total of 1.43 million shares worth $26.81 million.

Zai Lab Limited Stock Down 28.5%

Shares of NasdaqGM:ZLAB traded near $18.37 on Thursday. Zai Lab Limited has a market capitalization of approximately $2.08 billion. The stock's forward P/E ratio is not meaningful as the company is not currently profitable, with a negative EPS of -1.7. The stock's 52-week range is between $15.96 and $41.20, with a 50-day moving average of $19.84 and a 200-day moving average of $21.82. Zai Lab maintains a current ratio of 2.40 and a quick ratio of 1.84, with a debt-to-equity ratio of 35.03.

Recent Earnings

Zai Lab reported revenue of $453.28 million, though it experienced a revenue decline of 6.5%. The company also reported a negative net margin of 39.3% and a return on equity of -24.2%. The next earnings report is expected on August 6, 2026.

Analysts Set New Price Targets

On May 8, 2026, Citigroup maintained its 'buy' rating on Zai Lab and set a price target of $44. JP Morgan also maintained a 'buy' rating on March 18, 2026, with a target of $32. Cantor Fitzgerald echoed the 'buy' sentiment on February 27, 2026, with a target of $37. The consensus among analysts is a 'strong buy' with an average target price of $33.30 based on 12 analyst opinions.

About Zai Lab Limited

Zai Lab Limited is a biopharmaceutical company based in Pudong, China. It focuses on the discovery, development, and commercialization of treatments for cancer, immune disorders, neurological conditions, and infectious diseases. The company markets several products, including Zejula for ovarian cancer and VYVGART for myasthenia gravis. Zai Lab collaborates with major pharmaceutical firms like Pfizer and Amgen. Dr. Ying Du, Ph.D., leads the company, which employs 1,784 people.

Bottom Line

William Lis's recent share sale in Zai Lab Limited highlights insider activity within the company. Investors often track such transactions for insights, though they don't necessarily indicate future stock performance. The company's stock remains under close watch, given its strategic partnerships and analyst optimism, despite current financial challenges.